HBV基因型与干扰素及核苷类似物抗病毒治疗疗效的关系  

Relationship between HBV genotypes and efficacy of antiviral therapies

作　　者：李威[1] 申元英[1] 

机构地区：[1]大理学院基础医学院微生物学与免疫学教研室,云南大理671000

出　　处：《大理学院学报（综合版）》2007年第10期21-24,共4页Journal of Dali University

基　　金：国家自然科学基金资助项目(30560136)

摘　　要：目的:介绍乙型肝炎病毒(HBV)基因型与抗病毒治疗疗效关系的最新进展。方法:综合分析近年国内外有关HBV基因型与抗病毒治疗疗效关系的文献资料。结果:感染HBV基因型A的慢性乙型肝炎患者对干扰素治疗的应答率高于基因型D,基因型B高于基因型C;HBV基因型与核苷类似物治疗疗效的关系目前尚存争议;基因型E、F、G、H是否影响抗病毒疗效报道较少。结论:HBV基因型与抗病毒治疗疗效存在一定的相关性;HBV基因型的研究将有助于临床抗病毒治疗方案的优化。Objective： To introduce the research advances on the relationship between HBV genotypes and efficacy of antiviral therapies. Methods： To review and analyze the domestic and foreign literatures related to the relationship of HBV genotypes and efficacy of antiviral therapies in recent years. Results： Accumulating evidence indicated a better response to interferon in patients with chronic hepatitis A than those with D, and in patients with genotype B than those with C. In contrast, the impact of HBV genotypes on the therapeutic responses to nucleoside analogues remained controversial. Influence of genotype E, F, G or H on therapeutic responses need further study. Conclusion： The correlation exists between HBV genotypes and efficacy of antiviral therapies. Research on HBV genotypes will be beneficial to optimize antiviral therapeutic strategies.

关 键 词：乙型肝炎病毒 基因型 基因亚型 抗病毒治疗 

分 类 号：R373.21[医药卫生—病原生物学]